Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: oral metronidazole Clear all
Completed Early Phase 1 Interventional

Vaginal lIve Biotherapeutic RANdomized Trial

NCT06135974
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
LC106, LC115, Placebo, Metronidazole Oral
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 11, 2026, 9:46 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

NCT01723059
View directory record Official record
Conditions
Helicobacter Infection
Interventions
Standard Triple Therapy, Sequential Therapy
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 11, 2026, 9:46 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dental Intervention Plan for Chronic Kidney Disease Patients Awaiting or With Kidney Transplant

NCT04020458
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Periodontitis, Generalized, Moderate
Interventions
dental intervention
Procedure
Lead sponsor
Augusta University
Other
Eligibility
21 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 11, 2026, 9:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

NCT00048893
View directory record Official record
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)/TRICOM vaccine, filgrastim, sargramostim, cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, Mesna
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

NCT00108732
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Bicalutamide, Goserelin Acetate, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Recombinant Vaccinia-TRICOM Vaccine, Sargramostim
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Jacksonville, Florida • Chicago, Illinois • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

NCT04574583
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors
Interventions
SX-682, M7824, MVA-BN-CV301, recombinant fowlpox viral (FPV)-CV301
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 11, 2026, 9:46 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population

NCT01322971
View directory record Official record
Conditions
Vaginosis, Bacterial, Infertility, Miscarriage
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

Prophylactic Antibiotics After Cesarean

NCT03187106
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Cephalexin, Placebo, Metronidazole
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Austin, Texas • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 11, 2026, 9:46 PM EDT
Recruiting Phase 2 Interventional

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

NCT06627270
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma, Oral Cancer, Head and Neck Cancer, Head and Neck Carcinoma
Interventions
Metronidazole, Chlorhexidine
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

NCT01401023
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile
Interventions
Tigecycline
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
East Lansing, Michigan • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy

NCT00153517
View directory record Official record
Conditions
Vaginosis, Bacterial, Premature Birth, Birth Weight, Chorioamnionitis
Interventions
oral versus vaginal metronidazole
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
16 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Not applicable Interventional Results available

Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis

NCT00462020
View directory record Official record
Conditions
Perforated Appendicitis
Interventions
5 days of IV antibiotics (ceftriaxone and metronidazole), Home with oral antibiotics when eating (ampicillin/clavulanic acid)
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02236156
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Phoenix, Arizona • San Diego, California • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 11, 2026, 9:46 PM EDT
Terminated Phase 1 Interventional

Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity

NCT03954990
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Metronidazole Oral, Placebo Oral Tablet
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

NCT00464542
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 11, 2026, 9:46 PM EDT
Terminated Early Phase 1 Interventional

Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)

NCT04968951
View directory record Official record
Conditions
Ulcerative Colitis, FMT, Fecal Microbiota Transplant
Interventions
Metronidazole, Placebo, Vancomycin, Fecal Microbiota Transplantation
Drug · Biological
Lead sponsor
Ari M Grinspan
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 11, 2026, 9:46 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease

NCT01731236
View directory record Official record
Conditions
Dietary Modification
Interventions
Carnitine, Choline, Antibiotics, Choline and Aspirin, Carnitine and Aspirin
Dietary Supplement · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Antibiotics Versus Surgery for Treating Acute Appendicitis

NCT02447224
View directory record Official record
Conditions
Acute Uncomplicated Appendicitis
Interventions
1 gm IV ertapenem at enrollment, 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days, Appendectomy
Drug · Procedure
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 11, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01418365
View directory record Official record
Conditions
Healthy
Interventions
Metronidazole + MMX Mesalazine/mesalamine placebo, Metronidazole + MMX Mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 11, 2026, 9:46 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis

NCT02185456
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
750 mg metronidazole/ 200 mg miconazole vaginal suppository, Standard of care
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Sep 11, 2026, 9:46 PM EDT
Terminated Phase 1 Interventional Results available

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

NCT04296942
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
Interventions
Brachyury-TRICOM, Entinostat, M7824, Ado-trastuzumab emtansine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 11, 2026, 9:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Vaginal Microbiota Transplant

NCT04046900
View directory record Official record
Conditions
Recurrent Bacterial Vaginosis
Interventions
Vaginal microbiome transplant, Oral Metronidazole, Sterile saline
Biological · Drug · Other
Lead sponsor
Douglas Kwon
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 11, 2026, 9:46 PM EDT
Recruiting Phase 2 Interventional

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647
View directory record Official record
Conditions
Gram-negative Bacterial Infections
Interventions
ATM-AVI, BAT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Months to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 11, 2026, 9:46 PM EDT
Terminated Phase 4 Interventional Results available

A Randomized Controlled Trial of Treatment of Bacterial Vaginosis

NCT04578015
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 11, 2026, 9:46 PM EDT